
Quarterly report 2023-Q1
added 05-11-2023
Surgalign Holdings Net Debt 2011-2026 | SRGA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Surgalign Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.5 M | -50 M | -43.3 M | 170 M | 38.1 M | 24 M | 69.5 M | 67 M | 60.2 M | 50.3 M | -49.6 M | -45.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 170 M | -50 M | 23.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.72 | 0.95 % | $ 153 M | ||
|
AxoGen
AXGN
|
15.2 M | $ 33.03 | -4.08 % | $ 1.52 B | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.07 | -1.09 % | $ 862 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.25 | 1.79 % | $ 1.66 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 36.66 | -0.27 % | $ 5.46 K | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 62.57 | -0.4 % | $ 92.6 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.41 | 0.48 % | $ 266 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 34.54 | -0.72 % | $ 1.07 B | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.62 | 5.64 % | $ 38.6 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.76 | 1.35 % | $ 350 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.5 | 3.24 % | $ 131 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.26 | 0.26 % | $ 47.5 B | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.6 | 0.04 % | $ 122 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
-925 M | $ 170.52 | -0.05 % | $ 12.8 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.87 | 0.27 % | $ 1.14 M | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
-86.3 M | $ 6.42 | 3.38 % | $ 171 M | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 0.99 | 1.47 % | $ 16.8 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 96.6 | 0.38 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 85.01 | -2.12 % | $ 2.95 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.95 | -0.68 % | $ 374 M | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
LENSAR
LNSR
|
-10.2 M | $ 5.97 | -1.49 % | $ 71.4 M | ||
|
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.38 | 3.38 % | $ 56.1 M | ||
|
Medtronic PLC
MDT
|
23.6 B | $ 86.52 | -0.13 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
-148 M | $ 3.89 | -0.89 % | $ 575 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Myomo
MYO
|
-4.79 M | $ 0.69 | 3.22 % | $ 28.9 M |